Skip to main content
OpenTrials
Completed

NCT Number: NCT02442479

Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults

Resistance training has shown the most promise among interventions aimed to combat aging muscle atrophy as it enhances strength, power, and mobility function, but induces varying degrees of skeletal muscle hypertrophy as the investigators demonstrated in the initial 5-year funding period of this award (2001-2006). In the subsequent 5-year funding period (2007-2012), the investigators built on this prior work by using a dose-response approach in older adults - ultimately to optimize the treatment of age-related muscle atrophy. The investigators tested four, long-term resistance training prescriptions in older (60-75 yr) women and men to determine which prescription maximizes mechanisms driving muscle regrowth. One of the innovations in this project was the use of a 4-wk pre-training program to reach a plateau in the early, non-muscle mass adaptations, thereby establishing a true baseline from which both mechanisms of measurable muscle hypertrophy and functional consequences of hypertrophy could be studied in a tightly integrated fashion without bias in the subsequent experimental period. A randomized design was used to test the overarching hypothesis that a novel program of mixed strength and power training would optimize the anabolic environment to promote muscle hypertrophy and robust gains in performance. This hypothesis was tested with three specific aims.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UAB Center for Exercise Medicine

Birmingham, Alabama, 35294, United States

About this study

Resistance training has shown the most promise among interventions aimed to combat aging muscle atrophy as it enhances strength, power, and mobility function, but induces varying degrees of skeletal muscle hypertrophy as we demonstrated in the initial 5-year funding period of this award (2001-2006). In the subsequent 5-year funding period (2007-2012), we built on this prior work by using a dose-response approach in older adults - ultimately to optimize the treatment of age-related muscle atrophy. We tested four, long-term resistance training prescriptions in older (60-75 yr) women and men to determine which prescription maximizes mechanisms driving muscle regrowth (protein synthesis and myonuclear addition). One of the innovations in this project was the use of a 4-wk pre-training program to reach a plateau in the early, non-muscle mass adaptations, thereby establishing a true baseline from which both mechanisms of measurable muscle hypertrophy and functional consequences of hypertrophy could be studied in a tightly integrated fashion without bias in the subsequent experimental period. A randomized design was used to test the overarching hypothesis that a novel program of mixed strength and power training would optimize the anabolic environment to promote muscle hypertrophy and robust gains in performance. This hypothesis was tested with three specific aims.

Specific Aim 1. We determined the effects of manipulating intensity, recovery, and mode of contraction on rates of muscle hypertrophy and muscle mass-dependent improvements in tests of in vivo muscle performance among older women and men. In brief, the four training models were: (1) traditional high-resistance concentric-eccentric training (H) 3 d/wk (HHH3); (2) high-resistance concentric-eccentric training 2 d/wk (HH2); (3) 3 d/wk mixed model consisting of high-resistance concentric-eccentric training 2 d/wk separated by 1 bout of low-resistance, high-velocity, concentric only training (L) (HLH3); and (4) 2 d/wk mixed model consisting of high-resistance concentric-eccentric training 1 d/wk and low-resistance, high-velocity, concentric only training 1 d/wk (HL2). For Aim 1, we hypothesized that the HLH3 prescription would prove optimal overall for combined gains in muscle mass, strength, power, and fatigue resistance in both women and men, while HL2 would be the least effective program due to insufficient weekly loading.

Specific Aim 2. Myofiber hypertrophy requires net muscle protein synthesis, and advanced fiber expansion is facilitated by nuclear addition. We are conducting a comprehensive evaluation of: (1) key regulatory steps in the protein synthesis/degradation machinery; and (2) myonuclear addition and satellite cell activation/cell cycle regulation. Quantitative relationships between metabolic/molecular responses and the magnitude of muscle hypertrophy among older adults will enable us to identify underlying factors that respond differently to these four resistance training models, potentially in a gender-specific manner, thus revealing important processes that drive the hypertrophy adaptation. We hypothesized that muscle protein synthesis and myonuclear addition, along with key underlying regulatory processes, would be most favorably affected by the work-recovery cycle of 2 d/wk high-resistance loading (HLH3 and HH2 models), thereby optimizing the anabolic environment for muscle hypertrophy in both older women and men.

Specific Aim 3. To translate the findings under Aim 1 to clinically important outcomes, we determined the degree to which non-traditional resistance training programs lead to improvements in mobility function and weight-bearing exercise difficulty. We hypothesized that a less stressful weekly training regimen consisting of fewer high-resistance contractions (HLH3) and/or fewer training sessions (HH2) while achieving substantial hypertrophy would promote equal or better improvements in mobility function and weight-bearing exercise difficulty than the traditionally prescribed HHH3 program.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 60-75 years of age; BMI less than or equal to 30; passed comprehensive physical examination including resting electrocardiogram and a diagnostic graded exercise stress test with 12-lead electrocardiogram; able to exercise on a treadmill for 10 minutes; (female participants) at least 5 years post-menopausal.

Exclusion criteria

  • Neurological, musculoskeletal, or other disorder that would preclude completing resistance training and all performance tests; uncontrolled hypertension, unstable or exercise-induced angina pectoris or myocardial ischemia; diabetes mellitus; pregnancy; any other medical condition that would interfere with testing or increase one's risk of complications during exercise; lidocaine allergy; prescription anti-coagulants (e.g., Coumadin); current androgen or anabolic (e.g., GH, IGF-I) therapy; food allergy to cow's milk; history of regular resistance exercise during the previous 3 years; any contraindications to magnetic resonance imaging including pacemakers, aneurysm clips, or any other ferrous metal implants; current adherence to a weight reduction diet.

Treatment and study plan

Resistance training

Behavioral

Primary outcomes

  1. muscle mass

    Time frame: Change from baseline at week 35

    DXA-determined lean mass and thigh muscle mass

Secondary outcomes

  1. vastus lateralis muscle fiber size

    Time frame: Change from baseline at week 35

    type I and type II muscle fiber size by immunofluorescence microscopy

  2. maximum strength

    Time frame: Change from baseline at week 35

    one-repetition maximum voluntary strength

  3. maximum power

    Time frame: Change from baseline at week 35

    knee extension power

Other outcomes

  1. sit-to-stand difficulty

    Time frame: Change from baseline at week 35

    relative motor unit activation requirement

  2. steady state exercise difficulty

    Time frame: Change from baseline at week 35

    cardiorespiratory responses to 3 mph walking and 31 steps/min stair climbing

  3. mobility function

    Time frame: Change from baseline at week 35

    6-minute walk test

  4. muscle tissue molecular assays

    Time frame: Change from baseline at week 35

    translation initiation signaling, pro-inflammatory signaling, gene expression

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Collaborators

  • National Institute on Aging (NIA)
  • US Dairy Export Council

Registry information

Important dates

Study start
2007
Primary completion
2012
Study completion
2013
First posted
May 13, 2015
Registry last updated
Apr 25, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.